Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure is currently experiencing strong demand and growth in all markets due to a record revenue quarter, demonstrating strong execution on the commercial side. The recent CEMark for Optune Pax in locally advanced pancreatic cancer and the addition of TTFields as an NCCN Category 2A recommendation for brain metastases from NSCLC also support the company's anticipated growth. Additionally, NovoCure is engaging in strategic partnerships and exploring potential indications for TTFields, adding to the company's potential future success.

Bears say

NovoCure is seeing strong revenue growth but this is largely attributed to one-time revenue benefits and early launch metrics for Optune Pax, which may not be sustainable in the long-term. Despite an encouraging launch in Japan for Optune Lua, competition in the lung cancer market and limited treatment duration may pose challenges for sustained growth. Furthermore, with the failure of TRIDENT, concerns about durable adoption and franchise expansion remain. Lowering their price target to $46 due to potential long-term growth limitations.

Novocure (NVCR) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 5 analysts, Novocure (NVCR) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.